Advertisement
Advertisement
U.S. markets close in 1 hour 59 minutes
Advertisement
Advertisement
Advertisement
Advertisement

GBS Inc. (GBS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.7100-0.0101 (-1.40%)
As of 01:29PM EDT. Market open.
Advertisement

GBS Inc.

420 Lexington Avenue
Suite 300
New York, NY 10170
United States
646 828 8258
https://www.gbs.inc

Sector(s)Healthcare
IndustryMedical Devices
Full Time Employees7

Key Executives

NameTitlePayExercisedYear Born
Dr. Stephen Constantine Boyages M.D., MBBS, Ph.D.Interim CEO & Chairman20.51kN/A1958
Mr. Spiro Kevin Sakiris B.Bus, C.A., CA, Dip LawChief Financial Officer265.58kN/A1962
Mr. Harry SimeonidisPres of Asia Pacific - Sales & Marketing350.69kN/A1968
Ms. Victoria GavrilenkoOperations Mang.N/AN/A1983
Mr. Alex ArzenoVP of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

GBS Inc. operates as a biosensor diagnostic technology company. It offers Saliva Glucose Biosensor that uses saliva to measure glucose non-invasively. The company also focuses on developing COV2 test, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumour markers, hormones, and nucleic acid diagnostic modalities. It has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Corporate Governance

GBS Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement